Corcept Therapeutics
CORT
135 hedge funds and large institutions have $387M invested in Corcept Therapeutics in 2016 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 49 increasing their positions, 31 reducing their positions, and 13 closing their positions.
208% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 13
163% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $545K
58% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 31
48.05% more ownership
Funds ownership: 0% → 48.05% (+48%)
26% more capital invested
Capital invested by funds: $307M → $387M (+$80.5M)
23% more funds holding
Funds holding: 110 → 135 (+25)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.57M |
| 2 |
Renaissance Technologies
New York
|
+$7.42M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.94M |
| 4 |
Two Sigma Investments
New York
|
+$3.09M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
Investor AB
Stockholm,
Sweden
|
-$3.61M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$3.52M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$2.18M |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$1.25M |
| 5 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
-$1.06M |
CORT Hedge Fund Activity: Q4 2016 in Review
135 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2016, worth a combined $387M — up 26% from $307M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CORT positions and 13 closed out — a net gain of 27 holders — while 49 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $9.57M. The largest seller was Investor AB, cutting an estimated $3.61M.
- 135 institutional investors held Corcept Therapeutics (CORT) as of Q4 2016, up from 110 in Q3 2016.
- Funds reported $387M of Corcept Therapeutics stock for Q4 2016, up 26% quarter-over-quarter.
- 40 funds opened new Corcept Therapeutics positions in Q4 2016 and 13 closed out, a net change of +27 holders.
- The largest Corcept Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $9.57M added.
- The largest Corcept Therapeutics seller in Q4 2016 was Investor AB, an estimated $3.61M sold.
Based on aggregated 13F filings for Q4 2016.